Exhaled nitric oxide, nitrite/nitrate levels, allergy, rhinitis and asthma in the EGEA study
- Rachel Nadif1,2,
- Marta Rava1,2⇑,
- Brigitte Decoster3,
- Hélène Huyvaert3,4,
- Nicole Le Moual1,2,
- Jean Bousquet1,2,5,
- Valérie Siroux6,7,8,
- Raphaëlle Varraso1,2,
- Isabelle Pin6,7,8,
- Farid Zerimech4 and
- Régis Matran3
- 1INSERM, U1018, CESP Centre for Research in Epidemiology and Population Health, Respiratory and Environmental Epidemiology Team, Villejuif, France
- 2Univ. Paris-Sud, UMRS 1018, Villejuif, France
- 3Univ. Lille Nord de France, Lille, France
- 4Laboratoire de Biochimie, Centre de Biologie Pathologie, CHRU de Lille, Lille, France
- 5CHU Arnaud de Villeneuve, Montpellier, France
- 6Université Grenoble Alpes, Institut Albert Bonniot, Team of Environmental Epidemiology Applied to Reproduction and Respiratory Health, Grenoble, France
- 7INSERM, Institut Albert Bonniot, Team of Environmental Epidemiology Applied to Reproduction and Respiratory Health, Grenoble, France
- 8CHU de Grenoble, Institut Albert Bonniot, Team of Environmental Epidemiology Applied to Reproduction and Respiratory Health, Grenoble, France
- Marta Rava, Genetic and Molecular Epidemiology Group, Human Cancer Genetics Program, Spanish National Cancer Research Centre – Centro Nacional de Investigaciones Oncológicas (CNIO), Melchor Fernández Almagro, 3, 28029-Madrid, Spain. E-mail: mrava{at}cnio.es
Abstract
Although interest in biomarkers in the nitrate–nitrite–NO pathway has recently increased, associations between nitrite (NO2−) and nitrate (NO3−), and asthma, allergic sensitisation and rhinitis remain unclear.
The study aimed to evaluate the associations between NO2−/NO3− and exhaled fraction of nitric oxide (FeNO) levels with asthma, allergic sensitisation and rhinitis.
Plasma and exhaled breath condensate (EBC) NO2−/NO3− and FeNO levels were measured in 523 adults of the French Epidemiological study on Genetics and Environment of Asthma. Allergic sensitisation was defined by a positive skin prick test for at least one aeroallergen. Subjects were classified as non-sensitised, sensitised and as having allergic rhinitis.
Plasma NO2−/NO3− level was unrelated to any disease phenotypes. EBC NO2−/NO3− level was unrelated to any asthma phenotypes. EBC NO2−/NO3− and FeNO levels were correlated in sensitised subjects only (r=0.21±0.10, p=0.01). EBC NO2−/NO3− and FeNO levels were higher in sensitised than in non-sensitised subjects (adjusted geometric mean (95% CI): 2.36 (1.96–2.84) versus 1.72 (1.38–2.14) μmol per mg proteins, p=0.008; and 18.3 (16.7–20.0) versus 14.8 (13.3–16.5) ppb, p=0.0006, respectively), with gradual relationships from sensitised subjects to those with allergic rhinitis (p<0.0001).
Results suggest that EBC NO2−/NO3− and FeNO levels may be considered as biological markers of intensity of allergic sensitisation and rhinitis.
Abstract
The EGEA study: exhaled nitrate/nitrite/NO levels may be considered markers for intensity of allergy and rhinitis http://ow.ly/uKbxh
Introduction
The interest in measuring biological markers in exhaled breath condensate (EBC) in epidemiological studies of respiratory diseases has increased in the past years. Among the pathways involved in the pathophysiology of asthma, the metabolism of nitric oxide (NO), also called the nitrate–nitrite–NO pathway has taken a growing place in this research field [1]. NO metabolism is complex, and both NO measured by the exhaled fraction of NO (FeNO) and NO-related compounds such as nitrites (NO2−) and nitrates (NO3−) are relevant biological markers that may help to better understand the pathophysiology of asthma and allergy [2].
FeNO is the most studied of these, and it is commonly considered as a noninvasive indirect marker of airway inflammation [3]. Both epidemiological and clinical studies have shown increased level of FeNO in children and adults with asthma, and positive associations between FeNO and allergic sensitisation are consistent over the studies, regardless of rhinitis or asthma [4]. Studies on associations between NO2− and NO3− levels with asthma, allergy or rhinitis have led to more conflicting results both in adults and children [5–17]. Until now, none of these studies has simultaneously performed measurements of EBC NO2−/NO3− and FeNO levels in the same subjects. Recently, in a large number of adults from the French Epidemiological study on Genetics and Environment of Asthma (EGEA), EBC NO2−/NO3− and FeNO levels were found to be correlated in subjects without asthma [18].
Nitric oxide has different functions and roles in pathophysiology, which may be better explained by considering its compartmentalised production [19]. In this study, we compared the association between total NO2−/NO3− levels measured in two compartments (plasma and EBC) and FeNO levels with asthma, allergic sensitisation and rhinitis among 523 adults from the EGEA study. We hypothesised that the associations will be different depending on the compartments, biomarkers and outcomes studied.
Methods
Study design
Data used for the analyses were collected in the framework of the 12-year follow-up of EGEA. EGEA is a French cohort study based on an initial group of asthma cases and their first-degree relatives, and controls (first survey, n=2047; https://egeanet.vjf.inserm.fr/). The protocol and descriptive characteristics have been described previously [20, 21]. A follow-up of the initial cohort was conducted between 2003 and 2007 [22]. Among the alive cohort (n=2002), 92% (n=1845) completed a short, self-administered questionnaire and among them 1601 had a complete examination. All subjects responded to a questionnaire based on international standardised tools to diagnose asthma and to determine respiratory and allergic symptoms, treatments, and environmental exposures. The present cross-sectional analysis includes those who were adults at the second survey (≥16 years old, n=1570 adults) with available data on asthma, current rhinitis, allergic sensitisation, and available measurements of EBC NO2−/NO3− and FeNO levels (n=523). Subjects included in the analyses were younger, more often reported ever asthma and current rhinitis, and had higher levels of NO2−/NO3− and immunoglobulin E (IgE) than those not included in the analyses (n=1047). The two groups were similar for sex, smoking, current asthma status, allergic sensitisation, lung function tests, and eosinophil count (table S1 in supplementary data).
Ethical approval was obtained from the relevant institutional review board committees (Cochin Port-Royal Hospital and Necker-Enfants Malades Hospital, Paris, France). Written informed consent was signed by all participants.
Respiratory phenotypes
Subjects with ever asthma were defined by a positive answer to either: “Have you ever had attacks of breathlessness at rest with wheezing?”, or “Have you ever had asthma attacks?”, or if they were recruited as asthmatic cases at the first survey.
Allergic sensitisation was defined by a positive skin prick test (SPT+) with a mean wheal diameter ≥3 mm than the negative control for at least one of 12 aeroallergens (indoor: cat, Dermatophagoides pteronyssinus, Blattela germanica; outdoor: olive, birch, Parieteria judaica, timothy grass, Cupressus and ragweed pollen; and moulds: Aspergillus, Cladosporium herbarum and Alternaria tenuis). Subjects were classified as sensitised if they have one or more SPT+. Current rhinitis was defined by a positive answer to one of the two questions: “Have you ever had rhinitis?” or “Have you ever had hay fever?” and a positive answer to “have you had sneezing problems or a runny nose in the past 12 months?” Allergic rhinitis was defined as having both current rhinitis and one or more SPT+. Subjects were also classified in three groups as non-sensitised (no SPT+), sensitised only (having one or more SPT+ and no current rhinitis) and as having allergic rhinitis (one or more SPT+ and current rhinitis).
Eosinophilia was defined as eosinophil count ≥5%. Details on other phenotypes are given in supplementary data.
Biological phenotypes
EBC was collected with an RTubeTM (Respiratory Research Inc., Charlottesville, VA, USA) according to a standardised method. Briefly, the RTube was rinsed with deionised water and dried thoroughly. Participants breathed orally at tidal volumes into a mouthpiece attached to a cold condenser (−20°C). They were seated comfortably with a headrest. All headrests and back seats were tilted slightly to avoid any saliva contamination during breathing manoeuvres (see supplementary data for more details).
Total nitrite–nitrate (NO2−/NO3−) levels were measured in plasma and EBC as previously described [23]. All measurements were done in duplicate. Analytical intra-run imprecision was below 3%. Measurements with a coefficient of variation >15% and extreme outliers (n=7) were excluded from the analyses (see supplementary data for more details).
Measurements of FeNO were realised before other pulmonary function tests according to American Thoracic Society/European Respiratory Society recommendations (see supplementary data). The measurement was performed only in three of the five centres involved in the EGEA study, which explained in a large part the attrition on numbers of subjects included in the analysis compared to the total number. FeNO level was measured at 50 mL·s−1 flow rate as previously described [22].
Statistical methods
Joint distribution of asthma, SPT+ and current rhinitis was shown with a Venn diagram (fig. 1). Total plasma and EBC NO2−/NO3− and FeNO levels were log10-transformed as a result of their skewed distribution.
Also as part of the EGEA study, we previously reported that plasma NO2−/NO3− level was increased with leafy vegetable consumption and decreased in smokers and with storage time, that EBC NO2−/NO3− level was decreased in smokers and with exposure to ambient ozone concentration [23], and that FeNO level was associated with season of examination [22]. Furthermore, storage time and season of examination varied with centre. Therefore, estimates were adjusted for: 1) age, sex, smoking, leafy vegetable consumption and centre for plasma NO2−/NO3−; 2) age, sex, smoking, ambient ozone concentration and centre for EBC NO2−/NO3−; and 3) age, sex, height, smoking and centre for FeNO. Since the ratio of higher oxides of nitrogen (NOx, including NO2− and NO3−) to NO was reported to be more informative than each measurement alone by Nguyen et al. [13], the (NO2− + NO3−)/NO ratio (NOx/NO ratio) has also been studied.
As inhaled corticosteroids (ICS) use can decrease FeNO levels, and as NO2−/NO3− and FeNO are biological markers involved in the same pathway, association between ICS use and EBC NO2−/NO3− level was studied. Since increased body mass index (BMI)/obesity has been associated with lower FeNO level, estimates were also adjusted for BMI as a sensitivity analysis.
Associations between total NO2−/NO3− levels, FeNO levels, and the NOx ratio (NO2− + NO3−)/NO and asthma phenotypes, allergic sensitisation and current rhinitis were estimated with linear regression models. Parameter estimates were assessed by using generalised estimating equations (GEEs), with an exchangeable working correlation to account for the potential clustering within families (SAS MIXED procedure). The level of statistical significance was set at α=0.05. Two-sided p-values were reported for all association estimates. All analyses were conducted using SAS software, version 9.3 (SAS Institute, Inc., Cary, NC, USA).
Results
The characteristics of the 523 adults according to their asthma status are summarised in table 1. As expected, subjects with asthma had significantly higher eosinophilia, lower FEV1 % predicted, more often bronchial hyper-responsiveness (BHR), SPT+, and more often reported current rhinitis, than subjects without asthma. After adjustment for age, sex and smoking, the following associations between asthma and eosinophilia (OR 3.12, 95% CI 1.72–5.66), FEV1 (mean±sd 107.7±10.5 versus 97.5±11.0% pred), BHR (OR 4.18, 95% CI 2.66–6.57), SPT+ (OR 5.07, 95% CI 3.32–7.72) and current rhinitis (OR 4.62, 95% CI 3.11–6.85) were confirmed (all p<0.0005). Eosinophil count, IgE and FeNO levels were significantly higher in subjects with asthma than in those without (all p<0.0001). EBC NO2−/NO3− level was unrelated to ICS use (data not shown, p=0.5).
Pairwise association between EBC NO2−/NO3−, FeNO levels and blood eosinophil counts
EBC NO2−/NO3− levels were unrelated to eosinophil counts, whereas FeNO levels were positively associated with eosinophils in all subjects, both in non-sensitised and sensitised subjects (table 2). In sensitised subjects, EBC NO2−/NO3− was positively associated with FeNO levels.
The median (range) FeNO value in the population was 15.6 (2.4–99.0) ppb. Stratification according to this median value showed positive and significant association between EBC NO2−/NO3− level and allergic sensitisation in subjects above the median only (2.66 (2.06–3.43) versus 1.64 (1.18–2.28) μmol per mg proteins, p=0.01, and 2.03 (1.52–2.71) versus 1.76 (1.30–2.38) μmol per mg proteins, p=0.4, in subjects above and below the median, respectively).
Plasma and EBC NO2−/NO3−, FeNO levels and asthma and asthma-related phenotypes
Both plasma and EBC NO2−/NO3− levels were unrelated to ever asthma, current asthma, symptomatic score, and asthma control (data not shown, all p>0.3). Furthermore, plasma NO2−/NO3− level was unrelated to allergic sensitisation and current rhinitis.
Both plasma and EBC NO2−/NO3− levels were not related to eosinophilic asthma nor to age at asthma onset (table 3). As expected, a positive and significant association was observed between FeNO level and eosinophilic asthma (table 3), but no other significant association was observed.
EBC NO2−/NO3− and FeNO levels, NOx/NO ratio and allergic sensitisation
A positive association at borderline significance was observed between EBC NO2−/NO3− level and SPT+ (table 4). In a model adjusted for covariates, including asthma, EBC NO2−/NO3− level was positively and significantly associated with SPT+, and a positive association at borderline significance was observed with current rhinitis. Furthermore, positive and gradual increases in EBC NO2−/NO3− level were observed with quantitative SPT score (SPTQ) (fig. S1 in supplementary data), and when subjects were classified in the following groups: no SPT+, SPT+ only, and both SPT+ and current rhinitis (table 4 and fig. 2). The median (range) EBC NO2–/NO3– value in our population was 2.35 (1.14–4.9) μmol per mg proteins (table 1). Stratification according to this median value showed positive and significant associations between subjects above the median value and 1) allergic sensitisation (OR 1.92, 95% CI 1.25–2.97, p=0.003), 2) current rhinitis (OR 1.52, 95% CI 1.01–2.28, p=0.04), and 3) SPT+ only or both SPT+ and current rhinitis versus no SPT+ (OR 1.64, 95% CI 1.01–2.66, p=0.04, and OR 2.16, 95% CI 1.29–3.59, p=0.003, respectively) in GEE regression models with adjustement for age, sex, smoking, ambient ozone concentration, asthma and centre.
Similarly to EBC NO2−/NO3−, FeNO level was also positively related to allergic sensitisation expressed as SPT+ (table 4), and gradually increased with SPTQ (fig. S1), and with allergic sensitisation and current rhinitis. FeNO was also significantly and positively associated with current rhinitis. The associations between FeNO levels and SPT+, and current rhinitis were confirmed when BMI instead of height was added as a covariate in the models (data not shown).
No significant association were observed between the (NO2− + NO3−)/NO ratio (NOx/NO ratio) and SPT+, current rhinitis or both (table 4 and fig. 2). When analysing SPT+ to indoor, outdoor or mould allergens separately, EBC NO2−/NO3− levels showed positive and significant associations with sensitisation to mould allergens, and FeNO levels were positively associated to indoor allergens (table 4).
Discussion
The present study conducted on a large sample of adults with a precise phenotypic characterisation shows, for the first time, the similarities and differences for the associations of both FeNO and EBC NO2−/NO3− levels with asthma, allergic sensitisation and rhinitis. Results showed higher EBC NO2−/NO3− and FeNO levels in subjects with allergic sensitisation, with current rhinitis, and in particular when both are present. Only FeNO levels were found to be higher with asthma. EBC NO2−/NO3− and FeNO levels were positively associated in sensitised subjects only, and EBC NO2−/NO3− levels were found to be associated with allergic sensitisation in subjects with higher FeNO levels only.
The selection of the 523 subjects included in the present analyses was driven first by the random availability of the FeNO measurements in three of the five participating centres [22], and secondly by the availability of the other variables of interest. Definition of asthma case is very precise in our study, since asthmatic cases were recruited in chest clinics, and a procedure was set up to include true asthmatics, leading to a very limited risk of false-positives. Prevalence of BHR, measured by a methacholine challenge test was quite high in subjects without asthma. A possible explanation is that some of the subjects without asthma are first degree relatives of asthma cases. Nevertheless, this result is consistent with the relatively considerable number of asymptomatic subjects with BHR reported in cross-sectional epidemiological studies, ranging from 19.3 to 62.4%. Subjects included in the analyses had higher EBC NO2−/NO3− and FeNO levels than non-selected subjects. Other limitations of the present study were those commonly related to cross-sectional analyses of the data.
We reported no association between NO2−/NO3− level measured in plasma and any disease phenotypes. We previously reported that plasma and EBC NO2−/NO3− levels were not correlated [18]. The metabolism of NO is complex, and the production of NO2−/NO3− in plasma differs from that in EBC due to their compartmentalisation. In plasma NO2−/NO3− production derives from several sources, such as bacteria, enzymatic production and dietary sources [24]. In EBC ionised NO3− and NO2− (not volatile) may arise from NO after reaction with oxygen [25] or from activated immune cells present in the lining fluid of the lungs [26]. Overall, the specificities of the NO metabolism in plasma and in EBC may partly explain the lack of association with any clinical phenotypes in plasma. Our results are consistent with the hypotheses of Villanueva and Giulivi [19], for whom the compartmentalised production of NO better explains its different functions and roles in pathophysiology.
No association was found between total NO2−/NO3− level in EBC and asthma phenotypes, as previously reported in other studies [8, 14]. Contrary to our results, other studies have reported total NO2−/NO3− level in EBC to be elevated in subjects with asthma compared to healthy nonsmoking subjects [17], healthy nonatopic controls [5] or controls [9]. These conflicting results may be due to the very small number of subjects included in these studies, the various methodologies used for measuring NO2− and NO3− levels, the choice of the reference group for comparisons and other differences such as those related to phenotypes definition. Beside, information regarding allergic sensitisation was not available or subjects were defined as asthmatics if they had both asthma and allergy, suggesting that the increase in NO2−/NO3− level could be more related to allergy than to asthma. Furthermore, none of these previous studies have expressed the NO2−/NO3− level divided by the amount of proteins. As reported by Gessner and Wirtz [27], the measurement of total protein in EBC is important to confirm that protein and peptide markers are comparable between studies. They should always be performed in addition to specific markers investigated, and we previously found that NO2−/NO3− level in EBC was positively related to protein concentration in our study [28].
As reported in the literature [4, 29], positive associations between FeNO level and asthma, allergic sensitisation, and current rhinitis were found in this study. To our knowledge, our study reported for the first time similarities and differences for the associations of both FeNO and exhaled breath condensate NO2−/NO3− levels with asthma, allergic sensitisation and current rhinitis. We found positive associations between EBC NO2−/NO3− and FeNO levels in sensitised subjects, and between EBC NO2−/NO3− levels with allergic sensitisation in subjects with higher FeNO levels. Consistently, we found that both EBC NO2−/NO3− and FeNO levels increased with allergic sensitisation, with the number of SPT+, and that gradual relationships were observed between sensitised subjects only and those with both allergic sensitisation and rhinitis. An immediate practical utility could not be inferred from the results obtained in the framework of this epidemiological study, but taken together, our results suggest that EBC NO2−/NO3− and FeNO levels may be considered as biological markers of intensity of allergic sensitisation and rhinitis. Longitudinal studies are also needed to better understand the role of these biomarkers, in line with the idea that part of the "allergic march" involves oxidative and nitrosative processes.
By considering together EBC NO2−/NO3− and FeNO levels rather than each alone, our results provided complementary interesting information. To go further, we also studied the association between the NOx (NO2− + NO3−)/NO ratio and allergic sensitisation. Unfortunately, this ratio was not more informative than considering the measurement of EBC NO2−/NO3− alone. Contrary to our results, a ratio also including S-nitrosothiols, (NO2− + NO3− + S-nitrosothiols)/NO, was found to better evaluate inflammation in a case–control study on asthma [13] than the measurement of each oxide of nitrogen alone. This discrepancy in the results may be partly explained by the lack of measurement of S-nitrosothiols in our study, by the fact that we studied allergic sensitisation rather than inflammation, and/or by differences in study designs.
Overall, even if our results need to be replicated, they may suggest a role of the nitrate–nitrite–NO pathway in allergic sensitisation. We suggest that exposure to allergens results in uptake and proceeding by dendritic cells inducing the development of Th2 cells in sensitised individuals. Recent evidence indicates that airway epithelium also plays an important role in the allergic airway response by the release of interleukin (IL)-25, IL-33 and thymic stromal lymphopoietin (TSLP) which activate dendritic cells, basophils, eosinophils and Th2 cells [30, 31]. TSLP, IL-25 and IL-33 promote eosinophilia in airway mucosa by inducing IL-5 production. Eosinophilic airway inflammation may increase the NO concentration and subsequently produces the formation of NO2−, NO3− and reactive nitrogen species in EBC.
The results reported in this study highlight the complexity of NO metabolism. Initially considered completely inert, it is now apparent that nitrate and nitrite are physiologically recycled in blood and tissues to form NO and other bioactive nitrogen oxides [2]. They may be viewed as storage pools for NO-like bioactivity, thereby complementing the NO synthase-dependent pathway. NO and related compounds are produced by a wide variety of residential and inflammatory cells in the respiratory tract [32]. In response to allergens, both dendritic cells and airway epithelial cells are stimulated, and release various cytokines which activate dendritic cells, basophils, mast cells, eosinophils and Th2 cells, leading to eosinophil activation and proliferation [33]. We previously reported that FeNO level was positively associated with blood eosinophil counts [18], and there is in vitro evidence that human blood eosinophils produce NO and participate in the regulation of the NO pool in pulmonary tissues [34, 35]. Moreover, NO modulates the Th1/Th2 balance by favouring Th2 response and IL-5 production and thus recruiting eosinophils into the airways. Nevertheless, even if EBC NO2−/NO3− level can be viewed as a potential biological marker of allergy in our study, its specific role remains unknown, and mechanistic studies are required. As suggested through the results of the present study, and as reported by Erzurum and Gaston [36], the complexity of the nitrate–nitrite–NO pathway provides evidence that more targeted biological markers are needed for inclusion in a global scheme to help us to identify a type of response or phenotype for a given patient, requiring the integration of multiple factors in a system biology approach. Further studies are also warranted to better investigate the associations we observed in this epidemiological study, and the potential for a practical utility of our findings.
In conclusion, we report for the first time in a large epidemiological study that both total NO2−/NO3− and FeNO levels in EBC are associated with allergic sensitisation and rhinitis. The role of the nitrate–nitrite–NO pathway in the “allergic march” need to be further investigated in longitudinal studies. However, contrary to what has been shown with FeNO, we did not find an association of this biomarker with clinical phenotypes of asthma. Studying both FeNO and EBC NO2–/NO3– may help to disentangle the associations between NO metabolism and asthma, allergic sensitisation and rhinitis.
Acknowledgments
The authors thank all those who participated in the study and in the various aspects of the examinations, and all those who supervised the study in all centres. The authors are grateful to the three CIC-Inserm units of Necker, Grenoble and Marseille that supported the study and where subjects were examined. They are also grateful to the three biobanks in Lille (CIC-Inserm), Evry (Centre National de Genotypage) and Annemasse (Etablissement francais du sang) where biological samples are stored. They are indebted to all the individuals who participated, without whom the study would not have been possible.
The members of the EGEA cooperative group are as follows. Coordination: V. Siroux (epidemiology, principal investigator since 2013), F. Demenais (genetics), I. Pin (clinical aspects), R. Nadif (biology) and F. Kauffmann (principal investigator 1992–2012). Respiratory epidemiology: Inserm U 700, Paris: M. Korobaeff (Egea1) and F. Neukirch (Egea1); Inserm U 707, Paris: I. Annesi-Maesano (Egea1-2); Inserm CESP/U 1018, Villejuif: F. Kauffmann, N. Le Moual, R. Nadif, M.P. Oryszczyn (Egea1-2) and R. Varraso; Inserm U 823, Grenoble: V. Siroux. Genetics: Inserm U 393, Paris: J. Feingold; Inserm U 946, Paris: E. Bouzigon, F. Demenais and M.H. Dizier; CNG, Evry: I. Gut (now CNAG, Barcelona, Spain) and M. Lathrop (now University McGill, Montreal, QC, Canada). Clinical centres: Grenoble: I. Pin and C. Pison; Lyon: D. Ecochard (Egea1), F. Gormand and Y. Pacheco; Marseille: D. Charpin (Egea1) and D. Vervloet (Egea1-2); Montpellier: J. Bousquet; Paris Cochin: A. Lockhart (Egea1) and R. Matran (now in Lille); Paris Necker: E. Paty (Egea1-2) and P. Scheinmann (Egea1-2); Paris-Trousseau: A. Grimfeld (Egea1-2) and J. Just. Data and quality management: Inserm ex-U155 (Egea1): J Hochez; Inserm CESP/U 1018, Villejuif: N. Le Moual; Inserm ex-U780: C. Ravault (Egea1-2); Inserm ex-U794: N. Chateigner (Egea1-2); Grenoble: J. Quentin-Ferran (Egea1-2).
Footnotes
This article has supplementary material available from erj.ersjournals.com
Support statement: Research funded in part by PHRC-Paris, PHRC-Grenoble, ANR 05-SEST-020-02/05-9-97, ANR-06-CEBS, ANR-CES-2009, Region Nord Pas-de-Calais, Merck Sharp and Dohme (MSD), and the GA2LEN project, Global Allergy and Asthma European Network.
Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com
- Received November 19, 2013.
- Accepted February 28, 2014.
- ©ERS 2014